Neurofibromatosis Type 1 Accompanied by Craniofacial Pain: Literature Review and Descriptive Case

Neurofibromatosis type 1 (NF-1) is a genetic disease with characteristic neurofibromas and bony dysplasia that manifest throughout the body, including the craniofacial region. NF-1 patients are known to frequently report chronic pain in areas below the head; however, the matter of pain in the craniofacial region in this patient group has not been handled intensively so far, and studies have mainly focused on headaches. This article comprehensively reviews the related literature and reports a case of an NF-1 patient whose chief complaint was headache and pain in the temporomandibular joint area. Craniofacial pain is probably not an exceptional problem in NF-1, but the current inadequacy of related data is worrisome, considering the impact of pain on NF-1 prognosis and patient quality of life. The presence of craniofacial pain in NF-1 patients should be actively sought out in the diagnostic process and appropriate guidelines for its diagnosis and treatment should be established.

conservative treatment; craniofacial pain; headache; neurofibromatosis type 1; temporomandibular disorders

1. Metheny LJ, Cappione AJ, Skuse GR. Genetic and epigenetic mechanisms in the pathogenesis of neurofibromatosis type I. J Neuropathol Exp Neurol 1995;54:753–760.

2. Cunha KS, Barboza EP, Dias EP, Oliveira FM. Neurofibromatosis type I with periodontal manifestation. A case report and literature review. Br Dent J 2004;196:457–460.

3. Gutmman DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibomatosis 2. JAMA 1997;278:51–57.

4. Summers MA, Quinlan KG, Payne JM, Little DG, North KN, Schindeler A. Skeletal muscle and motor deficits in neurofibromatosis type 1. J Musculoskelet Neuronal Interact 2015;15: 161–170.

5. Sigillo R, Rivera H, Nikitakis NG, Sauk JJ. Neurofibromatosis type 1: A clinicopathological study of the orofacial manifestations in 6 pediatric patients. Pediatr Dent 2002;24:575–580.

6. Shapiro SD, Abramovitch K, Van Dis ML, et al. Neurofibromatosis: Oral and radiographic manifestations. Oral Surg Oral Med Oral Pathol 1984;58:493–498.

7. D’Ambrosio JA, Langlais RP, Young RS. Jaw and skull changes in neurofibromatosis. Oral Surg Oral Med Oral Pathol 1988; 66:391–396.

8. Cunha KS, Rozza-de-Menezes RE, Andrade RM, Almeida L, Janini M, Geller M. Oral manifestations of neurofibromatosis type 1 in children with facial plexiform neurofibroma: Report of three cases. J Clin Pediatr Dent 2015;39:168–171.

9. Javed F, Ramalingam S, Ahmed HB, et al. Oral manifestations in patients with neurofibromatosis type-1: A comprehensive literature review. Crit Rev Oncol Hematol 2014;91:123–129.

10. Lorson EL, DeLong PE, Osbon DB, Dolan KD. Neurofibromatosis with central neurofibroma of the mandible: Review of the literature and report of case. J Oral Surg 1997;35:733–738.

11. Wolters PL, Burns KM, Martin S, et al. Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life. Am J Med Genet A 2015;167:2103–2113.

12. Leung VK, Lee SW, Yuen NW, Kung NN, Loke TK. Epigastric pain in a patient with neurofibromatosis type 1. Hong Kong Med J 2005;11:213–215.

13. Okunoghae E, Starrett E, Gray B. Neurofibromatosis in a toddler with back pain. J Pediatr Health Care 2014;28:88–91.

14. Edmiston J. Leg pain in a teenager with a history of neurofibromatosis. JAAPA 2013;26:63–64.

15. Stavrinides V, Nasra S. A case of persistent foot pain in a neurofibromatosis type I patient. Case Rep Med 2012;2012:479632.

16. Protopapas A, Sotiropoulou M, Haidopoulos D, Athanasiou S, Loutradis D, Antsaklis A. Ovarian neurofibroma: A rare visceral occurrence of type 1 neurofibromatosis and an unusual cause of chronic pelvic pain. J Minim Invasive Gynecol 2011;18:520–524.

17. Leonard M, Harrington P. Painful glomus tumour of the thumb in an 11-year-old child with neurofibromatosis 1. J Hand Surg Eur Vol 2010;35:319–320.

18. Buckley M, Kuan S, Barton D. An unusual cause of collapse and neck pain. Emerg Med J 2008;25:857–858.

19. Batta AG, Gundian JC, Myers RP. Neurofibromatosis presenting as perineal pain and urethral burning. Urology 1989; 33:138–140.

20. Afridi SK, Leschziner GD, Ferner RE. Prevalence and clinical presentation of headache in a National Neurofibromatosis 1 Service and impact on quality of life. Am J Med Genet A 2015; 167:2282–2285.

21. Dworkin SF, LeResche L. Research diagnostic criteria for temporomandibular disorders: Review, criteria, examinations and specifications, critique. J Craniomandib Disord 1992;6: 301–355.

22. Derogatis LR. SCL-90-R: Symptom Checklist-90-R: Administration, Scoring, and Procedures Manual. Minneapolis, MN: NCS Pearson, 1975.

23. Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. Pain 1992;50:133–149.

24. Ohrbach R, Granger C, List T, Dworkin S. Preliminary development and validation of the Jaw Functional Limitation Scale. Community Dent Oral Epidemiol 2008;36:228–236.

25. Citak EC, Oguz A, Karadeniz C, Okur A, Memis L, Boyunaga O. Management of plexiform neurofibroma with interferon alpha. Pediatr Hematol Oncol 2008:25:673–678.

26. Kim A, Gillespie A, Dombi E, et al. Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas. Neurology 2009;73:1273–1279.

27. Tucker T, Friedman JM, Friedrich RE, Wenzel R, F Fünsterer C, Mautner VF. Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas. J Med Genet 2009;46:81–85.

28. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007;44:81–88.

29. Valeyrie-Allanore L, Ismaïli N, Bastuji-Garin S, et al. Symptoms associated with malignancy of peripheral nerve sheath tumours: A retrospective study of 69 patients with neurofibromatosis 1. Br J Dermatol 2005;153:79–82.

30. Leschziner GD, Golding JF, Ferner RE. Sleep disturbance as part of the neurofibromatosis type 1 phenotype in adults. Am J Med Genet A 2013;161:1319–1322.

31. Mouridsen SE, Sørensen SA. Psychological aspects of von Recklinghausen neurofibromatosis (NF1). J Med Genet 1995; 32:921–924.

32. North KN, Riccardi V, Samango-Sprouse C, et al. Cognitive function and academic performance in neurofibromatosis. 1: Consensus statement from the NF1 Cognitive Disorders Task Force. Neurology 1997;48:1121–1127.

33. Del Gallo F, Opp MR, Imeri L. The reciprocal link between sleep and immune responses. Arch Ital Biol 2014;152:93–102.

34. Patel SR, Zhu X, Storfer-Isser A, et al. Sleep duration and biomarkers of inflammation. Sleep 2009;32:200–204.

35. Zöller ME, Rembeck B. A psychiatric 12-year follow-up of adult patients with neurofibromatosis type 1. J Psychiatr Res 1999; 33:63–68.

36. Rumble ME, White KH, Benca RM. Sleep disturbances in mood disorders. Psychiatr Clin North Am 2015;38:743–759.

37. de Souza JB, Potvin S, Goffaux P, Charest J, Marchand S. The deficit of pain inhibition in fibromyalgia is more pronounced in patients with comorbid depressive symptoms. Clin J Pain 2009; 25:123–127.

38. Tonsgard JH. Clinical manifestations and management of neurofibromatosis type 1. Semin Pediatr Neurol 2006;13:2–7.

39. Clementi M, Battistella PA, Rizzi L, Boni S, Tenconi R. Headache in patients with neurofibromatosis type 1. Headache 1996; 36:10.

40. DiMario FJ Jr, Langshur S. Headaches in patients with neurofibromatosis-1. J Child Neurol 2000;15:235–238.

41. Ferner RE, Hughes RA, Weinman J. Intellectual impairment in neurofibromatosis 1. J Neurol Sci 1996;138:125–133.

42. Créange A, Zeller J, Rostaing-Rigattieri S, et al. Neurological complications of neurofibromatosis type1 in adulthood. Brain 1999;122:473–481.

43. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 2011;12: 570–584.

44. Sparaco M, Feleppa M, Lipton RB, Rapoport AM, Bigal ME. Mitochondrial dysfunction and migraine: Evidence and hypotheses. Cephalalgia 2006;26:361–372.

45. Herrero Valverde A, Moiron Simões R, Mera Campillo J, Palma

T. Headache in patient with neurofibromatosis type 1 [in Spanish]. Neurologia 2007;22:911–914.

46. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33:629–808.

47. Van Damme PA, Freihofer HP, De Wilde PC. Neurofibroma in the articular disc of the temporomandibular joint: A case report. J Craniomaxillofac Surg 1996;24:310–313.

48. Pasturel A, Bellavoir A, Cantaloube D, Dandrau JP, Perichaud P, Payement G. Temporomandibular joint dysfunction and neurofibromatosis. Apropos of a case [in French]. Rev Stomatol Chir Maxillofac 1989;90:17–19.

49. Migita K, Kawabe Y, Mori M, et al. Mixed connective tissue disease associated with von Recklinghausen’s neurofibromatosis. Intern Med 2001;40:363–364.

50. Martin S, Wolters PL, Toledo-Tamula MA, et al. Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy. Am J Med Genet A 2016; 170:1462–1470.

51. Swann AC. Major system toxicities and side effects of anticonvulsants. J Clin Psychiatry 2001;62(suppl):s16–s21.

52. Rodriguez RF, Castillo JM, Castillo MP, et al. Hydrocodone/acetaminophen and tramadol chlorhydrate combination tabletsfor the management of chronic cancer pain: A double-blind comparative trial. Clin J Pain 2008;24:1–4.

53. Kim A, Gillespie A, Dombi E, et al. Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas. Neurology 2009;73:1273–1279.

54. Helmers KM, Irwin KE. Physical therapy as conservative management for cervical pain and headaches in an adolescent withneurofibromatosis type 1: A case study. J Neurol Phys Ther 2009; 33:212–223.

55. Skaribas I, Calvillo O, Delikanaki-Skaribas E. Occipital peripheral nerve stimulation in the management of chronic intractable occipital neuralgia in a patient with neurofibromatosis type 1: A case report. J Med Case Rep 2011;5:174.

56. Rocco ML, Rosenblatt MA. Ultrasound-guided peripheral nerve block in a patient with neurofibromatosis. Reg Anesth Pain Med 2011;36:88–89.

57. Baujat B, Krastinova-Lolov D, Blumen M, Baglin AC, Coquille F, Chabolle F. Radiofrequency in the treatment of craniofacial plexiform neurofibromatosis: A pilot study. Plast Reconstr Surg 2006;117:1261–1268.

58. Wise JB, Cryer JE, Belasco JB, Jacobs I, Elden L. Management of head and neck plexiform neurofibromas in pediatric patients with neurofibromatosis type 1. Arch Otolaryngol Head Neck Surg 2005;131:712–718.

59. Merker VL, Bredella MA, Cai W, et al. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis. Am J Med Genet A 2014;164:1431–1437.

60. Wolkenstein P, Zeller J, Revuz J, Ecosse E, Leplège A. Quality-of-life impairment in neurofibromatosis type 1: A cross-sectional study of 128 cases. Arch Dermatol 2001;137:1421–1425.

61. Hofman KJ, Harris EL, Bryan RN, Denckla MB. Neuro fibromatosis type 1: The cognitive phenotype. J Pediatr 1994;124:s1–s8.

62. Dilts CV, Carey JC, Kircher JC, et al. Children and adolescents with neurofibromatosis 1: A behavioral phenotype. J Dev Behav Pediatr 1996;17:229–239.

63. Garwood MM, Bernacki JM, Fine KM, Hainsworth KR, Davies WH, Klein-Tasman BP. Physical, cognitive, and psychosocial predictors of functional disability and health-related quality of life in adolescents with neurofibromatosis-1. Pain Res Treat 2012; 2012:975364.

64. Page PZ, Page GP, Ecosse E, Korf BR, Leplege A, Wolkenstein P. Impact of neurofibromatosis 1 on quality of life: A cross-sectional study of 176 American cases. Am J Med Genet A 2006; 140:1893–1898.